211. |
212. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysisTanja Čufer, Tudor Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopović, Jacek Jassem, Dragana Jovanovic, Zhasmina MIhaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski, 2020, izvirni znanstveni članek Povzetek: Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.
Ključne besede: non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe
Objavljeno v DiRROS: 24.07.2020; Ogledov: 1935; Prenosov: 1118
 Celotno besedilo (341,24 KB)
Gradivo ima več datotek! Več... |
213. Elevated ozone prevents acquisition of available nitrogen due to smaller root surface area in poplarTanja Mrak, Klemen Eler, Ovidiu Badea, Yasutomo Hoshika, Elisa Carrari, Elena Paoletti, Hojka Kraigher, 2020, izvirni znanstveni članek Povzetek: Aims Poplars are ecologically and economically important tree genus, sensitive to ozone (O3). This study aimed to investigate modifying effects of elevated O3 on poplar root response to nutrient addition. Methods In pot experiment, young trees of an O3-sensitive Oxford poplar clone (Populus maximoviczii Henry x berolinensis Dippel) growing in soil with three levels of P (0, 40 and 80 kg ha-1) and two levels of N (0 and 80 kg ha-1) were exposed to three levels of O3 (ambient - AA, 1.5 x AA, 2.0 x AA) at a free air exposure facility. After one growing season, root biomass, fine root (<2 mm) nutrient concentrations and ratios, and fine root morphology were assessed. Results Nitrogen addition resulted in an up to +100.5% increase in coarse and fine root biomass under AA, and only up to +46.3% increase under 2.0 x AA. Elevated O3 and P addition had a positive effect, while N had a negative effect on P concentrations in fine roots. Nitrogen limitation for root growth expressed as a N:P ratio was more pronounced at elevated O3. Nitrogen addition increased root surface area per soil volume by +78.3% at AA and only by +9.9% at 2.0 x AA. Conclusions Smaller root surface area per soil volume at elevated O3 prevented acquisition of available N, rendering N fertilization of young poplar plantations in such conditions economically and environmentally questionable.
Ključne besede: fine roots, nitrogen, phosphorus, Populusmaximoviczii x berolinensis, ozone, Poplar
Objavljeno v DiRROS: 16.06.2020; Ogledov: 1958; Prenosov: 1076
Celotno besedilo (775,68 KB)
Gradivo ima več datotek! Več... |
214. |
215. Napotki za premagovanje neželenih učinkov sistemskega zdravljenja raka : kaj morate vedeti?Simona Borštnar, Marjana Bernot, Tanja Čufer, Marika Horvat, Denis Mlakar-Mastnak, Janja Ocvirk, Bojana Pajk, Monika Sonc, Snežana Umičević, Marjetka Uršič-Vrščaj, Metka Zajc, Branko Zakotnik, 2007, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: onkologija
Objavljeno v DiRROS: 10.06.2020; Ogledov: 2014; Prenosov: 585
Celotno besedilo (3,72 MB) |
216. |
217. Folikularni limfom : vodnik za bolnikeTanja Južnič Šetina, 2017, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: etiologija, komplikacije, recidiv, bolniki, psihološka pomoč
Objavljeno v DiRROS: 04.06.2020; Ogledov: 1966; Prenosov: 585
Celotno besedilo (1,15 MB) |
218. Rak požiralnika : kaj morate vedeti o bolezniMarko Boc, Martina Reberšek, Janja Ocvirk, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Maja Ebert Moltara, Tanja Mesti, Franc Anderluh, Vaneja Velenik, Irena Oblak, Jasna But-Hadžić, Ajra Šečerov Ermenc, Nada Rotovnik-Kozjek, Matevž Srpčič, 2014, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje, paliativna oskrba, prehrana
Objavljeno v DiRROS: 04.06.2020; Ogledov: 1850; Prenosov: 523
Celotno besedilo (634,73 KB) |
219. Rak trebušne slinavke : kaj morate vedeti o bolezniMartina Reberšek, Marko Boc, Irena Oblak, Jernej Benedik, Zvezdana Hlebanja, Janja Ocvirk, Neva Volk, Tanja Mesti, Maja Ebert Moltara, Tomaž Milanez, Franc Anderluh, Vaneja Velenik, Jasna But-Hadžić, Ajra Šečerov Ermenc, Ana Jeromen, Nada Rotovnik-Kozjek, Katja Kogovšek, Aleš Tomažič, 2014, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, bolniki, simptomi, diagnostika, zdravljenje, bolečina, dietna terapija, paliativna oskrba
Objavljeno v DiRROS: 04.06.2020; Ogledov: 2210; Prenosov: 681
Celotno besedilo (1,22 MB) |
220. Informacije za bolnike, zdravljene z dabrafenibom in trametinibom : vodnik za kombinirano zdravljenjeJanja Ocvirk, Martina Reberšek, Marko Boc, Tanja Mesti, 2019, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: onkologija, kemoterapija, kombinirano zdravljenje
Objavljeno v DiRROS: 03.06.2020; Ogledov: 1551; Prenosov: 378
Celotno besedilo (289,85 KB) |
